Newsbenzinga
BeOne Medicines Advances Chemotherapy-Free Lymphoma Strategy
· Published
Article summary
BeOne Medicines reported positive Phase 3 BRUKINSA data in mantle cell lymphoma, reducing progression or death risk by 43% ahead of planned filings.
An excerpt from the original article.
Comments —
Loading comments…